PH12018500445B1 - Use of anti-cd40 antibodies for treatment of lupus nephritis - Google Patents

Use of anti-cd40 antibodies for treatment of lupus nephritis

Info

Publication number
PH12018500445B1
PH12018500445B1 PH1/2018/500445A PH12018500445A PH12018500445B1 PH 12018500445 B1 PH12018500445 B1 PH 12018500445B1 PH 12018500445 A PH12018500445 A PH 12018500445A PH 12018500445 B1 PH12018500445 B1 PH 12018500445B1
Authority
PH
Philippines
Prior art keywords
antibodies
lupus nephritis
treatment
therapeutic
compositions
Prior art date
Application number
PH1/2018/500445A
Other languages
English (en)
Other versions
PH12018500445A1 (en
Inventor
Scott Ronald Brodeur
Thomas B Freeman
Gerald Henry Nabozny
Meera RAMANUJAM
Paul Scholl
Juergen STEFFGEN
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PH12018500445A1 publication Critical patent/PH12018500445A1/en
Publication of PH12018500445B1 publication Critical patent/PH12018500445B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2018/500445A 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis PH12018500445B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (2)

Publication Number Publication Date
PH12018500445A1 PH12018500445A1 (en) 2018-09-10
PH12018500445B1 true PH12018500445B1 (en) 2022-08-10

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2018/500445A PH12018500445B1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Country Status (16)

Country Link
US (3) US20170058038A1 (OSRAM)
EP (1) EP3344655B1 (OSRAM)
JP (2) JP2018529661A (OSRAM)
KR (1) KR20180039172A (OSRAM)
CN (1) CN107922501A (OSRAM)
AU (1) AU2016317028B2 (OSRAM)
BR (1) BR112018001907A2 (OSRAM)
CA (1) CA2993996A1 (OSRAM)
CL (1) CL2018000317A1 (OSRAM)
DK (1) DK3344655T5 (OSRAM)
ES (1) ES2969968T3 (OSRAM)
HU (1) HUE063528T2 (OSRAM)
MX (1) MX390653B (OSRAM)
PH (1) PH12018500445B1 (OSRAM)
PL (1) PL3344655T3 (OSRAM)
WO (1) WO2017040566A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20240149979A (ko) * 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
EA202190094A1 (ru) * 2018-06-29 2021-04-21 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против cd40 для применения в лечении аутоиммунного заболевания
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
ZA936128B (en) 1992-08-21 1995-02-20 Genentech Inc Method for treating a LFA-1 mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
AU2005323515A1 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
ES2354865T3 (es) * 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
RS57114B1 (sr) * 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
AU2012249454B2 (en) * 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
EP3344655B1 (en) 2023-07-26
CA2993996A1 (en) 2017-03-09
ES2969968T3 (es) 2024-05-23
MX2018002447A (es) 2018-06-15
JP2021185169A (ja) 2021-12-09
PH12018500445A1 (en) 2018-09-10
DK3344655T5 (da) 2024-10-07
WO2017040566A1 (en) 2017-03-09
BR112018001907A2 (pt) 2018-09-25
DK3344655T3 (da) 2023-10-09
JP2018529661A (ja) 2018-10-11
AU2016317028B2 (en) 2021-09-09
US20170058038A1 (en) 2017-03-02
HUE063528T2 (hu) 2024-01-28
KR20180039172A (ko) 2018-04-17
AU2016317028A1 (en) 2018-02-22
MX390653B (es) 2025-03-21
US20190177420A1 (en) 2019-06-13
EP3344655A1 (en) 2018-07-11
CL2018000317A1 (es) 2018-07-20
US20230265203A1 (en) 2023-08-24
CN107922501A (zh) 2018-04-17
PL3344655T3 (pl) 2024-02-19

Similar Documents

Publication Publication Date Title
PH12018500445A1 (en) Use of anto-cd40 antibodies for treatment of lupus nephritis
IL288278A (en) Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
ZA202006610B (en) Compositions for the treatment of skin conditions
MY192927A (en) Fused bicyclic compounds for the treatment of disease
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
ZA202007055B (en) Compositions for the treatment of skin conditions
MY177915A (en) Il-21 antibodies
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
PH12019502694A1 (en) Anti-trkb antibodies
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
IL263336B (en) Compounds for the treatment of symphysiolysis
EA201890629A1 (ru) Применение антител к cd40 для лечения волчаночного нефрита